Boston Scientific Announces TGA Approval and Launch of Platinum Chromium Element(TM) Stent Series

By Boston Scientific Corporation, PRNE
Sunday, March 14, 2010

Third-Generation Drug-Eluting Stents Now Available in Australia

MASCOT, Australia, March 15, 2010 - Boston Scientific Corporation (NYSE: BSX) announces that it
received Australian Therapeutic Goods Administration (TGA) approval for its
PROMUS(R) Element(TM) and TAXUS(R) Element(TM) Stent Systems, the Company's
third-generation drug-eluting stent (DES) technology. The Element Stent
Systems incorporate a novel platinum chromium alloy with an innovative stent
design and an advanced catheter delivery system. The Company is now marketing
the PROMUS Element and TAXUS Element Stent Systems in Australia.

The platinum chromium alloy used in the Element Stent Series
is a generation beyond cobalt chromium, and is engineered specifically for
coronary stenting. This proprietary alloy, when combined with the innovative
Element Stent design, offers greater radial strength and flexibility than
older alloys such as cobalt chromium, used in the Xience V(TM) and Xience
Prime(TM) Stents. Platinum chromium (PtCr) also provides superior visibility
and minimized recoil compared to studied cobalt chromium stents.

"The platinum chromium alloy and new stent design used in the
Element Stent System represent significant innovations in drug-eluting stent
technology," said Professor Ian Meredith of Monash Medical Centre, Melbourne.
"In my experience, the Element platform offers a stenting option that
provides enhanced deliverability and visibility with excellent conformability
and low recoil. I believe it may offer performance improvements that could
simplify procedures and allow treatment of a broader range of patients."

"We are proud to introduce our third-generation drug-eluting
stent to physicians and patients in Australia," said Mark Wallwork, Managing
Director, Boston Scientific Australia. "The Element Stent Series is the
latest example of Boston Scientific's commitment to DES market leadership and
continued innovation. It gives physicians the choice of two proven drug and
polymer combinations - used in millions of patients worldwide - on an
entirely new stent platform. We are confident our Element Stent Series will
further extend our global DES leadership."

The first implant of the PROMUS Element Stent was performed by Professor
Ian Meredith.

Supporting Clinical studies

The PROMUS Element Everolimus-Eluting Coronary Stent System is
used in the PLATINUM clinical trial, which completed enrollment of 1,531
patients in September 2009 at 133 sites worldwide including five in
Australia. PLATINUM is a randomized, controlled, pivotal trial designed to
support U.S. Food and Drug Administration (FDA) and Japanese Ministry of
Health, Labor and Welfare (MHLW) approval of the PROMUS Element Stent System.

The TAXUS Element Paclitaxel-Eluting Coronary Stent is used in
the PERSEUS Clinical Program. The PERSEUS program includes more than 90
clinical sites, including three in Australia, four in New Zealand and one in
Singapore. The trial design includes both a randomized, single-blind,
non-inferiority workhorse arm (2.75 to 4.00 mm diameter stents), and a small
vessel (2.25 and 2.50 mm diameter) superiority trial.

The PROMUS Element Stent System received CE Mark approval in
October 2009. The Company anticipates FDA approval for the PROMUS Element
system in 2012. The TAXUS Element Stent System was launched in select
international markets in May 2009. CE Mark approval for the TAXUS Element
system is expected in the second quarter of 2010, and FDA approval is
expected in 2011.

In the U.S., the PROMUS Element and TAXUS Element Stent
Systems are investigational devices and are limited by applicable law to
investigational use only and are not available for sale. In the EEA, the
TAXUS Element Stent System is CE mark pending and not available for sale.

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words. These
forward-looking statements are based on our beliefs, assumptions and
estimates using information available to us at the time and are not intended
to be guarantees of future events or performance. These forward-looking
statements include, among other things, statements regarding clinical trials,
regulatory approvals, competitive offerings, product performance and our
market position. If our underlying assumptions turn out to be incorrect, or
if certain risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases, have affected and
in the future (together with other factors) could affect our ability to
implement our business strategy and may cause actual results to differ
materially from those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place undue reliance on
any of our forward-looking statements.

Factors that may cause such differences include, among other things:
future economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property; litigation;
financial market conditions; and, future business decisions made by us and
our competitors. All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that may
affect our future operations, see Part I, Item 1A - Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A - Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file hereafter. We
disclaim any intention or obligation to publicly update or revise any
forward-looking statements to reflect any change in our expectations or in
events, conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will differ from
those contained in the forward-looking statements. This cautionary statement
is applicable to all forward-looking statements contained in this document.

1. To date. Test conducted at Boston Scientific. Data on file.

2. Data on file. Compared to XIENCE V(TM) and Endeavor(TM) stents. Bench
tested. Tests performed on TAXUS(TM) Element(TM) stent. Indicative of
performance of PROMUS(TM) Element(TM). XIENCE is a trademark of Abbott
Laboratories group, Endeavor is a trademark of Medtronic Corporation.

Contact: Geraldine Varoqui, Director International Public Relation, Tel: +49-2102-489-461, Mob: +49-170-782-85-58, varoquig at

will not be displayed